China Pharma (CPHI) Stock Price, News & Analysis

Company Overview

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Key Stats

• Today's Range: $1.47 to $1.65
• 50-Day Range: $1.50 to $14.12
• 52-Week Range: $1.20 to $3.35
• Volume: 173,872 shs
• Average Volume: 65,420 shs
• Market Capitalization: $5.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

China Pharma Stock Analysis - MarketRank™

China Pharma scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for China Pharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

China Pharma has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.96% of the float of China Pharma has been sold short.

Short Interest Ratio / Days to Cover

China Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in China Pharma has recently decreased by 29.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

China Pharma does not currently pay a dividend.

Dividend Growth

China Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.96% of the float of China Pharma has been sold short.

Short Interest Ratio / Days to Cover

China Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in China Pharma has recently decreased by 29.65%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

China Pharma has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for China Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, China Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.32% of the stock of China Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

CPHI Stock Analysis - Frequently Asked Questions

How have CPHI shares performed this year?

China Pharma's stock was trading at $23.00 on January 1st, 2025. Since then, CPHI stock has decreased by 93.1% and is now trading at $1.59.
View the best growth stocks for 2025 here.

How were China Pharma's earnings last quarter?

China Pharma Holdings, Inc. (NYSE:CPHI) released its quarterly earnings results on Wednesday, August, 15th. The company reported ($100.00) earnings per share for the quarter. The business earned $3.17 million during the quarter. China Pharma had a negative trailing twelve-month return on equity of 63.93% and a negative net margin of 85.56%.

When did China Pharma's stock split?

China Pharma shares reverse split before market open on Tuesday, April 15th 2025. The 1-10 reverse split was announced on Friday, April 4th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 14th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of China Pharma?

Shares of CPHI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of China Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that China Pharma investors own include iBio (IBIO), Biocept (BIOC), Micron Technology (MU), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP) and Bionano Genomics (BNGO).

Company Calendar

• Last Earnings: 8/15/2018
• Today: 6/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CPHI
• CIK: 1106644
• Web: www.chinapharmaholdings.com
• Phone: 8689866811730
• Fax: 86-898-6681-9024
• Employees: 250
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.08 million
• Net Margins: -85.56%
• Pretax Margin: -85.56%
• Return on Equity: -63.93%
• Return on Assets: -31.42%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 0.79
• Quick Ratio: 0.26

Sales & Book Value

• Annual Sales: $4.30 million
• Price / Sales: 1.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.70 per share
• Price / Book: 2.27

Miscellaneous

• Outstanding Shares: 3,262,000
• Free Float: 15,918,000
• Market Cap: $5.19 million
• Optionable: Not Optionable
• Beta: 0.77